Advertisement

Urolithiasis pp 141-144 | Cite as

Effective Prevention of Calcium-Oxalate Crystal Formation in vitro and in vivo by Pentosan Polysulfate

  • H. Osswald
  • G. Weinheimer
  • I.-D. Schütt
  • W. Ernst

Abstract

The “inhibitor theory” as an alternative to the “matrix theory” postulates that stone-forming patients have a deficiency of effective inhibitors of crystal growth in their urine (1). A number of inhibitors of calcium-oxalate (CaOx) crystal formation have been described including pentosan polysulfate (2). Since Danielson et al. (3) reported the possible efficacy of pentosan polysulfate (PPS) in reducing the recurrence rate of CaOx stone formation in man, it was of interest to establish a test system with in vitro and in vivo experiments that allow quantitation of the assumed beneficial effects of PPS. In addition, a reliable test system can provide the basis for a systematic search for effective inhibitors of CaOx crystal formation in the kidney and urine. For comparison we also studied three types of chondroitin sulfate in vivo and in vitro.

Keywords

Chondroitin Sulfate Calcium Oxalate CaOx Crystal Pentosan Polysulfate Lithogenic Diet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    WG Robertson and M Peacock, Pathogenesis of urolithiasis, ia: “Urolithiasis: Etiology, Diagnosis”, H-J Schneider, ed., Springer, Berlin (1985).Google Scholar
  2. 2.
    WG Robertson, AB Latif, DS Scurr, AM Caswell, GW Drach, and AD Randolph, Inhibitors of calcium oxalate crystallization in urine from stone-formers and normals, in: “Urinary Stone”, R Ryall, JG Brockis, V Marshall, and B Finlayson, eds., Churchill Livingstone, Melbourne (1984).Google Scholar
  3. 3.
    BG Danielson, F Fellström, U Backman, K Holmgren, G Johansson, M Lindsjö, S Ljunghall, and B Wiström, Glycosaminoglycans and renal stone disease. Clinical effects of pentosan polysulphate (Elmiron), in: “Fortschritte der Urologie und Nephrologie, 25. Pathogenase und Klinik der Harnsteine, XII”, W Vahlensieck und G Grasser, eds., Steinkopff, Darmstadt (1987).Google Scholar
  4. 4.
    B Finlayson, The concept of a continuous crystallizer, Invest. Urol. 9: 258 (1972).PubMedGoogle Scholar
  5. 5.
    W Ernst and H Osswald, X-ray micro-analysis of kidney stone formation in rats under lithogenic treatment, Proc. XIth Int. Congr. on Electron Microscopy, Kyoto, p. 2343 (1986).Google Scholar
  6. 6.
    X Martin, PG Werness, JH Bergert, and LH Smith, Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth, J. Urol. 132: 786 (1984).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • H. Osswald
    • 1
  • G. Weinheimer
    • 1
  • I.-D. Schütt
    • 1
  • W. Ernst
    • 1
  1. 1.Department of PharmacologyGoedecke Research InstituteFreiburgGermany

Personalised recommendations